

DAFTAR PUSTAKA

- Aarão, T. L. de S. *et al.* (2018) 'Nerve growth factor and pathogenesis of leprosy: Review and update', *Frontiers in Immunology*, 9(MAY), pp. 1–8. doi: 10.3389/fimmu.2018.00939.
- Amiruddin, M.D., 2019. *Penyakit kusta: Sebuah pendekatan klinis*. Firstbox Media.
- Amiruddin, M. Dali. 2012. *Penyakit Kusta; Sebuah Pendekatan Klinis*. Brilian Internasional, Jakarta.
- Bilik, L., Demir, B. and Cicek, D. (2017) 'Leprosy Reactions', *Hansen's Disease - The Forgotten and Neglected Disease*. doi: 10.5772/INTECHOPEN.72481.
- Bungin, C., Lumban Toruan, V.M. and Riasiti, Y. (2020) 'THE CORRELATION BETWEEN LEPROSY TYPE AND GRADE OF DISABILITY IN LEPROSY PATIENTS IN SAMARINDA', 8(1).
- Cendaki, Q. A. (2018) 'The Findings of Mycobacterium leprae DNA Existence in the Air as an Indication of Leprosy Transmission from Respiratory System', *Jurnal Kesehatan Lingkungan*, 10(2), p. 181. doi: 10.20473/jkl.v10i2.2018.181-190.
- Deviana, R. (2019) *CONTINUING PROFESSIONAL DEVELOPMENT Rifampisin Ofloksasin Minosiklin (ROM) sebagai Terapi Alternatif Morbus Hansen*.
- Fabel, A. *et al.* (2019) 'Pathogenesis of Leprosy: An Insight Into B Lymphocytes and Plasma Cells', *The American Journal of dermatopathology*, 41(6), pp. 422–427. doi: 10.1097/DAD.0000000000001310.

- Fatmala, K.A. (2016) 'Analisis faktor yang berhubungan dengan kepatuhan minum obat kusta di Kecamatan Pragaan', *Jurnal Berkala Epidemiologi*, 4(1), pp. 13–24. Available at: <https://doi.org/10.20473/jbe.v4i1.13-24>.
- Fava, V.M., Dallmann-Sauer, M. and Schurr, E. (2020) 'Genetics of leprosy: today and beyond', *Human Genetics*, 139(6–7), pp. 835–846. Available at: <https://doi.org/10.1007/s00439-019-02087-5>.
- Graham A, Furlong S, Margoles LM, Owusu K. Clinical management of leprosy reactions. *Infectious Diseases in Clinical Practice*. 2010;18:235-238
- Hadi, M. I., & Kumalasari, M. L. F. (2017). *Kusta Stadium Subklinis Faktor Risiko Dan Permasalahannya. Kusta Stadium Subklinis Faktor Risiko dan Permasalahannya*. Surabaya: Program Studi Arsitektur Universitas Islam 88 Negeri Sunan Ampel Surabaya.
- Kaimal, S. and Thappa, D. (2009) 'Relapse in leprosy', *Indian Journal of Dermatology, Venereology and Leprology*. Medknow Publications and Media Pvt. Ltd, pp. 126–135. Available at: <https://doi.org/10.4103/0378-6323.48656>.
- Kementerian Kesehatan Republik Indonesia. Profil Kesehatan Indonesia 2019: Kemenkes RI; 2019.
- Kementrian Kesehatan RI. 2018. *Hapuskan Stigma dan Diskriminasi Terhadap Kusta*. Diakses pada tanggal 13 Mei 2022 dari <https://pusdatin.kemkes.go.id/resources/download/pusdatin/infodatin/infoDatin-kusta-2018.pdf>

- Kumar, A., Girdhar, A. and Girdhar, B. (2012) ‘Six months fixed duration multidrug therapy in paucibacillary leprosy: risk of relapse and disability in Agra PB cohort study’. Available at: <https://doi.org/10.1136/bmjopen-2012>.
- Kumar, A., Girdhar, A. and Girdhar, B. (2015) ‘A randomized controlled trial to compare cure and relapse rate of paucibacillary multidrug therapy with monthly rifampicin, ofloxacin, and minocycline among paucibacillary leprosy patients in Agra District, India’, *Indian Journal of Dermatology, Venereology and Leprology*, 81(4), pp. 356–362. Available at: <https://doi.org/10.4103/0378-6323.159929>.
- Kumar, A., Girdhar, A. and Girdhar, B.K. (2013) *Twelve months fixed duration WHO multidrug therapy for multibacillary leprosy: incidence of relapses in Agra field based cohort study*.
- Lazo-Porras, M. *et al.* (2020) ‘World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: A systematic review and meta-analysis’, *BMC Infectious Diseases*. BioMed Central Ltd. Available at: <https://doi.org/10.1186/s12879-019-4665-0>.
- Maymone, M.B.C., Laughter, M., *et al.* (2020) ‘Leprosy: Clinical aspects and diagnostic techniques’, *Journal of the American Academy of Dermatology*. Mosby Inc., pp. 1–14. Available at: <https://doi.org/10.1016/j.jaad.2019.12.080>.
- Maymone, M.B.C., Venkatesh, S., *et al.* (2020) ‘Leprosy: Treatment and management of complications’, *Journal of the American Academy of Dermatology*. Mosby Inc., pp. 17–30. Available at: <https://doi.org/10.1016/j.jaad.2019.10.138>.

- Moestopo, O., Gunawan, H., & Dahlan, A. (2016). Comparison of Effectiveness between Rifampicin Ofloxin-Minocycline Regimen and Multidrug Therapy-World Health Organization in Multibacillary Leprosy Patients. *Althea Medical Journal*, 3(4), 661-665.
- Nery, J.A. da C. *et al.* (2013) 'Understanding the type 1 reactional state for early diagnosis and treatment: a way to avoid disability in leprosy', *Anais Brasileiros de Dermatologia*, 88(5), p. 787. Available at: <https://doi.org/10.1590/ABD1806-4841.20132004>.
- Nery, J.A.C. *et al.* (2021) 'Low rate of relapse after twelve-dose multidrug therapy for hansen's disease: A 20-year cohort study in a brazilian reference center', *PLoS Neglected Tropical Diseases*, 15(5). Available at: <https://doi.org/10.1371/journal.pntd.0009382>.
- Penna, G.O. *et al.* (2017) 'Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients', *PLoS Neglected Tropical Diseases*, 11(7). Available at: <https://doi.org/10.1371/journal.pntd.0005725>.
- Rachmawati, S. (2014) 'Penyakit Kusta di Bangkalan Tahun 1934-1939', *E-Journal Pendidikan Sejarah*, 2(1), pp. 83-91.
- Raj Sapkota, B. *et al.* (2008) *A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsona.*
- Rajkumar, P. *et al.* (2021) 'Low risk of relapse and deformity among leprosy patients who completed multi-drug therapy regimen from 2005 to 2010: A

- cohort study from four districts in south india’, *PLoS Neglected Tropical Diseases*, 15(11). Available at: <https://doi.org/10.1371/journal.pntd.0009950>.
- Sarode, G. *et al.* (2020) ‘Epidemiological aspects of leprosy’, *Disease-a-Month*, 66(7). Available at: <https://doi.org/10.1016/j.disamonth.2019.100899>.
- WHO (2018) *Guidelines for the Diagnosis, Treatment and Prevention of Leprosy*.
- WHO (2022) *Leprosy*. Available at: <https://www.who.int/news-room/fact-sheets/detail/leprosy> (Accessed: 13 May 2022).
- World Health Organization. Weekly epidemiological record. Global leprosy update, 2019.2020; Available from : <https://apps.who.int/iris/bitstream/handle/10665/334140/WER9536-eng-fre.pdf?sequence=1&isAllowed=y> [cited 7 November 2022]
- Zhu, J. *et al.* (2017) ‘Case report: Therapeutic dilemma of refractory erythema nodosum leprosum’, *American Journal of Tropical Medicine and Hygiene*, 96(6), pp. 1362–1364. Available at: <https://doi.org/10.4269/ajtmh.16-0118>.